Have you been wondering about how you can participate in the upcoming FDA trials for Scenesse? Me, too. Fortunately I was able to get a podcast interview with Lachlan Hay, Head of Global Network and Communications, Clinuvel AG.
Lachlan explains exactly how Scenesse works on vitiligo and thoroughly unravels the FDA trial process which Scenesse will undergo. He also gives us an informative background on Clinuvel, the developers of Scenesse, and describes the stipulations and process one needs to know in order to be a part of the FDA trials for Scenesse.
I hope you enjoy the podcast…and if you do, please go to the vitiligo friends fan page & click “like”. Cheers!
Who is Lachlan Hay, Head of Global Network and Communications, Clinuvel AG?
Originally trained as a journalist, Lachlan joined Clinuvel’s Melbourne team in 2007 to work on the company’s online projects. He has since assumed a broader role, relocating to Switzerland to lead Clinuvel’s communications programs.
Lachlan is active in Clinuvel’s social media and patient relations programs, where the company is recognized as an innovator within the drug development industry, posting regularly to the company’s blog, Facebook pages and Twitter feed.
Prior to joining Clinuvel, Lachlan worked in marketing and sponsorship roles for a not-for-profit organization in Australia.
* As a side note, I’d like to add that it has just been a pleasure talking with Lachlan over the past few months. His passion for the work he does is both inspiring and contagious. I feel very fortunate that we have someone like Lachlan Hay in our corner.